Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes

Journal of Diabetes Investigation

Volumn 3, Issue 1, 2012, Pages 70-79

  Yabe, Daisuke ^a   Watanabe, Koin ^a   Sugawara, Kenji ^a   Kuwata, Hitoshi ^a   Kitamoto, Yuka ^a   Sugizaki, Kazu ^a   Fujiwara, Shuichi ^a   Hishizawa, Masahiro ^a   Hyo, Takanori ^a   Kuwabara, Kyoko ^a   Yokota, Kayo ^a   Iwasaki, Masahiro ^a   Kitatani, Naomi ^a   Kurose, Takeshi ^a   Inagaki, Nobuya ^b   Seino, Yutaka ^a  

^a KANSAI ELECTRIC POWER CO   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Extraction; Immunoassay; Incretin

Indexed keywords

ALCOHOL; DIPEPTIDYL PEPTIDASE IV; FATTY ACID; GASTRIC INHIBITORY POLYPEPTIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOOD DEPRIVATION; FUNCTION TEST; HORMONE RELEASE; HUMAN; IMMUNOASSAY; JAPANESE; LIMIT OF DETECTION; MALE; MEAL TOLERANCE TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; SOLID PHASE EXTRACTION;

EID: 84857216684     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2011.00141.x     Document Type: Article

References (30)

1. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-165.
2. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-1439.
3. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Invest 2010; 1: 9-23.
4. Yabe D, Kuroe A, Lee S, et al. Little enhancement of meal-induced GLP-1 secretion in Japanese: comparison of type 2 diabetes and healthy controls. J Diabetes Invest 2010; 1: 56-59.
5. Aaboe K, Knop FK, Vilsboll T, et al. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2010; 12: 323-333.
6. Deacon CF, Holst JJ. Immunoassays for the incretin hormones GIP and GLP-1. Best Pract Res Clin Endocrinol Metab 2009; 23: 425-432.
7. LaMarca CJ, Perregaux DG, Preston GM, et al. Comparison and validation of multiple commercially available methods for active GLP-1 quantification: sample extraction is a ubiquitous requirement. In: ENDD2009. Washington, D.C. 2009.
8. Parker HE, Reimann F, Gribble FM. Molecular mechanisms underlying nutrient-stimulated incretin secretion. Expert Rev Mol Med 2010; 12: e1.
9. Parker HE, Habib AM, Rogers GJ, et al. Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 2009; 52: 289-298.
10. Reimann F, Habib AM, Tolhurst G, et al. Glucose sensing in L cells: a primary cell study. Cell Metab 2008; 8: 532-539.
11. Ross SA, Brown JC, Dupre J. Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus. Diabetes 1977; 26: 525-529.
12. Takemura J, Seino Y, Tsuda K, et al. Hypersecretion of gastric inhibitory polypeptide induced by glucose ingestion in diabetes mellitus. Endocrinol Jpn 1981; 28: 17-21.
13. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717-3723.
14. Vilsboll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001; 50: 609-613.
15. Vollmer K, Holst JJ, Baller B, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008; 57: 678-687.
16. Nauck MA, Vardarli I, Deacon CF, et al. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2010; 54: 10-18.
17. Seino Y, Nanjo K, Tajima N, et al. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. J Diabetes Invest 2010; 1: 212-228.
18. Seino Y, Nanjo K, Tajima N, et al. Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus. Diabetol Int 2010; 1: 2-20.
19. Zhu L, Tamvakopoulos C, Xie D, et al. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38). J Biol Chem 2003; 278: 22418-22423.
20. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
21. Yamada Y, Fukuda K, Fujimoto S, et al. SUIT, secretory units of islets in transplantation: an index for therapeutic management of islet transplanted patients and its application to type 2 diabetes. Diabetes Res Clin Pract 2006; 74: 222-226.
22. Dai H, Gustavson SM, Preston GM, et al. Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects. Diabetes Obes Metab 2008; 10: 506-513.
23. Conlon JM, Bridgeman M, Alberti KG. The nature of big plasma somatostatin: implications for the measurement of somatostatin-like immunoreactivity in human plasma. Anal Biochem 1982; 125: 243-252.
24. Tsuda K, Sakurai H, Seino Y, et al. Somatostatin-like immunoreactivity in human peripheral plasma measured by radioimmunoassay following affinity chromatography. Diabetes 1981; 30: 471-474.
25. Lee S, Yabe D, Nohtomi K, et al. Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes. Endocr J 2010; 57: 119-126.
26. Nielsen LB, Ploug KB, Swift P, et al. Co-localisation of the Kir6.2/SUR1 channel complex with glucagon-like peptide-1 and glucose-dependent insulinotrophic polypeptide expression in human ileal cells and implications for glycaemic control in new onset type 1 diabetes. Eur J Endocrinol 2007; 156: 663-671.
27. Roberge JN, Brubaker PL. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology 1993; 133: 233-240.
28. Ritzel R, Orskov C, Holst JJ, et al. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 1995; 38: 720-725.
29. Schirra J, Sturm K, Leicht P, et al. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J Clin Invest 1998; 101: 1421-1430.
30. Meier JJ, Ueberberg S, Korbas S, et al. Diminished glucagon suppression after beta-cell reduction is due to impaired alpha-cell function rather than an expansion of alpha-cell mass. Am J Physiol Endocrinol Metab 2011; 300: E717-723.